Longevity-focused healthtech startup Biopeak has raised $2.7 million in a follow-on funding round led by NKSquared, the venture capital firm of Zerodha co-founder Nikhil Kamath.
This is Kamath’s second investment in the startup after putting in $1.43 million in August 2024.
The startup will use the fresh funds to scale its operations, including opening a new flagship clinic in Bengaluru, expanding its team, and strengthening its specialist clinics and diagnostics. It also plans to invest more in its proprietary AI tools, research infrastructure, and clinical programmes.
Founded by Rishi Pardal and Shiva Subramanian, Biopeak focuses on improving healthspan through a longevity-led approach. It combines cellular and molecular diagnostics, advanced imaging, and AI-driven insights to create personalised health plans.
The startup describes its model as a “family health office” approach that looks at long-term health and prevention, not just treatment. Biopeak’s technology profiles more than 130 biomarkers using blood tests, genetic and epigenetic analysis, microbiome mapping, hormonal analysis, salivary cortisol rhythms, and whole-exome functional genomics. These are paired with high-resolution imaging such as MRI, CT, DXA, ECHO, and carotid IMT.
The platform is designed to detect health risks early, track changes over time, and suggest targeted interventions related to nutrition, sleep, stress, and overall lifestyle.
The Bengaluru-based startup claims that it works with institutions like IISc and Longevity India to better adapt health data to South Asian genetics, environment, and lifestyle. This helps improve the relevance and accuracy of its care. Biopeak launched its first clinic in Bengaluru last year and plans to open another clinic in the city soon.
